Regulatory
-
5 Feb, 2026
Spago Nanomedical bokslutskommuniké januari-december 2025
-
5 Feb, 2026
Spago Nanomedical year-end report January-December, 2025
-
24 Nov, 2025
Spago Nanomedical announces outcome of oversubscribed rights issue
-
24 Nov, 2025
Spago Nanomedical offentliggör utfall i övertecknad företrädesemission
-
29 Oct, 2025
Spago Nanomedical beslutar om en företrädesemission om cirka 25 MSEK för att avancera Tumorad
-
29 Oct, 2025
Spago Nanomedical resolves on a rights issue of approximately SEK 25 million to advance Tumorad
-
29 Oct, 2025
Spago Nanomedical delårsrapport januari-september 2025
-
29 Oct, 2025
Spago Nanomedical interim report January-September 2025
-
14 Oct, 2025
Synligt tumörupptag och rekommenderad doshöjning i Spago Nanomedicals fas I/IIa-studie Tumorad-01
-
14 Oct, 2025
Visible tumor uptake and recommended dose increase in Spago Nanomedicals’s Phase I/IIa study Tumorad-01